Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACESO: ESO-101 in Active Eosinophilic Esophagitis
NCT04849390Phase 2Completed
- Sponsor
- EsoCap AG
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of ESO-101 in eosinophilic esophagitis (EoE), sponsored by EsoCap AG. Started Jun 2021; status: completed.
02
Drugs
ESO-101
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04849390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849390.